Q3 2025 · 13F-HR
Atle Fund Management ABholdings as filed
Filed 2025-11-04 · accession 0001381843-25-000009
$27.0M
Reported value
38
Positions
2025-09-30
Period end
The Brief · Atle Fund Management AB · Q3 2025
AI · grounded in 13F
Atle Fund Management AB established a new position in Eli Lilly & Co LLY valued at $3.02M. The fund also initiated new stakes in AbbVie Inc ABBV for $2.26M and Neurocrine Biosciences Inc NBIX for $1.53M. Additional new positions include Merck & Co. Inc MRK and Thermo Fisher Scientific Corp TMO.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 532457108 | LLY | Eli Lilly & Co | $3.0M | 11.2% | 37,244 | Common | SOLE |
| 00287Y109 | ABBV | AbbVie Inc | $2.3M | 8.40% | 92,105 | Common | SOLE |
| 64125C109 | NBIX | Neurocrine Biosciences Inc | $1.5M | 5.67% | 102,625 | Common | SOLE |
| 58933Y105 | MRK | Merck & Co. Inc | $1.4M | 5.32% | 160,913 | Common | SOLE |
| 883556102 | TMO | Thermo Fisher Scientific Corp | $1.4M | 5.18% | 27,147 | Common | SOLE |
| 07725L102 | ONC | BeiGene Ltd | $1.1M | 4.07% | 30,333 | Common | SOLE |
| 10806X102 | BBIO | Bridgebio Pharma Inc | $963,444 | 3.57% | 174,722 | Common | SOLE |
| 03073E105 | COR | Cencora Inc | $949,197 | 3.52% | 28,608 | Common | SOLE |
| 46120E602 | ISRG | Intuitive Surgical Inc | $935,682 | 3.47% | 19,707 | Common | SOLE |
| 375558103 | GILD | Gilead Sciences Inc | $921,159 | 3.42% | 78,169 | Common | SOLE |
| 101137107 | BSX | Boston Scientific Corp | $898,420 | 3.33% | 86,680 | Common | SOLE |
| 863667101 | SYK | Stryker Corporation | $893,584 | 3.31% | 22,769 | Common | SOLE |
| G01767105 | ALKS | Alkermes PLC | $805,386 | 2.99% | 252,875 | Common | SOLE |
| 501147102 | KRYS | Krystal Biotech, Inc | $790,707 | 2.93% | 42,191 | Common | SOLE |
| 92532F100 | VRTX | Vertex Pharmaceuticals Inc | $738,675 | 2.74% | 17,766 | Common | SOLE |
| 604749101 | MIRM | Mirum Pharmaceuticals Inc | $728,516 | 2.70% | 93,605 | Common | SOLE |
| N62509109 | NAMS | NewAmsterdam Pharma Co NV | $584,612 | 2.17% | 193,625 | Common | SOLE |
| 450056106 | IRTC | iRhythm Technologies Inc | $547,610 | 2.03% | 29,991 | Common | SOLE |
| 28176E108 | EW | Edwards Lifesciences Corp | $542,105 | 2.01% | 65,659 | Common | SOLE |
| 14149Y108 | CAH | Cardinal Health Inc | $504,854 | 1.87% | 30,297 | Common | SOLE |
| 902673102 | UFPT | UFP Technologies Inc | $487,081 | 1.81% | 22,986 | Common | SOLE |
| N5749R100 | 2GH | Merus N.V. | $479,766 | 1.78% | 47,999 | Common | SOLE |
| 834203309 | SLNO | Soleno Therapeutics Inc | $431,720 | 1.60% | 60,156 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION Medicines Inc | $423,178 | 1.57% | 85,355 | Common | SOLE |
| 031162100 | AMGN | Amgen Inc | $413,620 | 1.53% | 13,806 | Common | SOLE |
| 252131107 | DXCM | Dexcom Inc | $363,418 | 1.35% | 50,872 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $341,560 | 1.27% | 203,755 | Common | SOLE |
| 254604101 | IRON | Disc medicine inc | $320,529 | 1.19% | 45,690 | Common | SOLE |
| 91324P102 | UNH | Universal Health Services Inc | $297,933 | 1.10% | 13,727 | Common | SOLE |
| 413197104 | HRMY | Harmony Bioscience Holdings | $269,397 | 1.00% | 92,074 | Common | SOLE |
| 05370A108 | RNAGBP | Avidity Biosciences Inc | $240,427 | 0.89% | 51,978 | Common | SOLE |
| 21833P301 | CRBP | Corbus Pharmaceuticals Holding | $235,802 | 0.87% | 175,582 | Common | SOLE |
| 03940C100 | ACLXGBX | Arcellx Inc | $224,281 | 0.83% | 25,732 | Common | SOLE |
| 86627T108 | SMMT | Summit Therapeutics Inc | $203,404 | 0.75% | 92,737 | Common | SOLE |
| 05280R100 | AUTL | Autolus Therapeutics PLC | $202,402 | 0.75% | 1,169,634 | Common | SOLE |
| 15102K100 | CELC | Celcuity Inc | $194,869 | 0.72% | 37,157 | Common | SOLE |
| 589492107 | MREO | Mereo Biopharma Group PLC | $167,282 | 0.62% | 764,901 | Common | SOLE |
| 47103J105 | JANX | Janux Therapeutics Inc | $129,265 | 0.48% | 49,820 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.